Article Data

  • Views 408
  • Dowloads 134

Original Research

Open Access

The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer

  • P. Valenzuela1,3,*,
  • S. Mateos1
  • E. Tello1
  • M. J. Lopez-Bueno1
  • N. Garrido1
  • M. J. Gaspar2

1Department of Obstetrics and Gynecology, Spain

2Department of Biochemisty,“Principe de Asturias" Hospital, Spain

3Department of Especialidades Medicas. Alcala de Henares University. Madrid, Spain

DOI: 10.12892/ejgo20030160 Vol.24,Issue 1,January 2003 pp.60-62

Published: 10 January 2003

*Corresponding Author(s): P. Valenzuela E-mail:

Abstract

Purpose of investigation: The clinical use of tumor markers during breast cancer follow-up is still surrounded by controversy. The objective of this study consisted of determining the contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer patients as applied to clinical practice.

Methods: Three hundred and eighteen cases of women with breast cancer were analyzed retrospectively as far as the sensitivity, the specificity and the positive and negative predictable values of the CA 15.3 and CEA markers.

Results: Of the 318 patients, 59 suffered a relapse during the study. After evaluation of both markers the sensitivity was 56.8% (CA 15.3: 47.4%), the specificity 85.3% (CA 15.3: 88.4%), the positive predictable value was 46.4% (CA 15.3: 48.2%) and the negative predictable value was 89.41% (CA 15.3: 88%).

Conclusions: The low sensitivity of studied tumor markers proved of limited use on a clinical scale.

Keywords

Breast cancer; Tumor markers; CA 15.3; CEA; Follow-up

Cite and Share

P. Valenzuela,S. Mateos,E. Tello,M. J. Lopez-Bueno,N. Garrido,M. J. Gaspar. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. European Journal of Gynaecological Oncology. 2003. 24(1);60-62.

References

[1] Rosen P. R., Groshen S., Saigo P. E., Kinne D. W., Hellman S.: "A long-term follow-up study of survival in stage I (TINO MO) and stage II (TINIMO) breast carcinoma". J. Clin. Oneal., 1989, 7, 355.

[2] Hayes D. F.: "Serum (circulating) tumor markers for breast cancer". Recent Results Cancer Res., 1996, 140, 101.

[3] Gold P., Freedman S. 0.: "Specific carcinoembryonic antigens of the human digestive system". J. Exp. Med., 1965, 122, 467.

[4] Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J.: "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus bening breast tumors". Hybridorna, 1984, 3, 223.

[5] Winchester D. P., Sener S. F., Khandekar J. D., Oviedo M. A., Cunningham M. P., Caprini J. A. et al.: "Symptomatology as an indicator of recurrent or metastatic breast cancer". Cancer, 1979, 43, 956.

[6] Stierer M., Rosen H. R.: "Influence of early diagnosis on prognosis of recurrent breast cancer". Cancer, 1989, 64, 1128.

[7] Broyn T., Froyen J.: "Evaluation of routine follw-up after surgery for breast carcinoma". Acta Chir. Scand., 1982, 148, 401.

[8] American Society of Clinical Oncology: "Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer". J. Clin. Oneal., 1996, 14, 2843.

[9] Bast Re. Jr.,R avdin P.,H ayes D. F.,B ates S.,F ritsche H. Jr,J essup J. M. et al.: "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology". J. Clin Oncol., 2001, 19, 1865.

[10] Lumachi F., Brandes A. A., Boccagni P.. Polistina F., Favia G., D'amico D. F.: "Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3". Anticancer Res., 1999, 19, 4485.

[11] Lauro S., Trasatti L., Bordin F., Lanzetta G., Bria E., Gelibter A et al.: "Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients". Anticancer Res., 1999, 19, 3511.

[12] Slitterlin M., Bussen S., Trott S., Caffier H.: "Predicitve value of CEA and CA 15-3 in the follow up of invasive breast cancer" Anticancer Res., 1999, 19, 2567.

[13] Sauer H.: "Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer". Anticancer Res., 1997, 17, 3059.

[14] Molina R., Jo J., Filella X., Zan6n G., Farrus B., Munoz M. et al. "C-erbB-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients". Anticancer Res., 1999, 19, 2551.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top